Pick a Topic:
Find info on a:
ClotCare complies with the HONcode standard for trustworthy health
information:
verify here.
ClotCare is a member organization of the Coalition to Prevent Deep Vein Thrombosis. Click here to learn more about the Coalition to Prevent Deep Vein Thrombosis and DVT Awareness Month, which is held each March.
|
Non-steroidal Anti-inflamatory Drugs (NSAIDs) Receive Greater Scrutiny in the Wake of Vioxx Withdrawal
Marie B. Walker
January 2005
As has been widely publicized in the major media outlets, the pharmaceutical company Merck pulled its non-steroidal anti-inflamatory drug (NSAID) Vioxx from the market in late September in response to a study indicating that the drug increases the risk of stroke and heart attack. Since the withdrawal of Vioxx, other drugs in this class have received greater scrutiny. Studies have suggested that drugs such as Celebrex, Bextra, and Aleve increase a patient's risk of stroke and heart attack. Below are links to news stories seen in the major media outlets relating to Celebrex, Bextra, and Aleve.
FDA Asks Pfizer to Stop Misleading Celebrex Ads
Read the story on Fox News
Read the story on CNN
Read the story on Reuters
Celebrex and Naproxen (Aleve) May Increase Stroke & Heart Attack Risk
Read the story on Fox News
Read the story on CNN
Read the story on Reuters
|
ClotCare is a 501(c)(3) non-profit organization generously supported by your tax-deductible donations and grants from our industry supporters.
New Postings:
Click here to view full list of new postings
|